

Fabian A Mendoza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9048971/publications.pdf>

Version: 2024-02-01

22
papers

816
citations

623188

14
h-index

794141

19
g-index

22
all docs

22
docs citations

22
times ranked

1080
citing authors

#	ARTICLE	IF	CITATIONS
1	Description of 12 Cases of Nephrogenic Fibrosing Dermopathy and Review of the Literature. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 35, 238-249.	1.6	241
2	Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosisâ€“Associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2016, 68, 210-217.	2.9	91
3	A Prospective Observational Study of Mycophenolate Mofetil Treatment in Progressive Diffuse Cutaneous Systemic Sclerosis of Recent Onset. <i>Journal of Rheumatology</i> , 2012, 39, 1241-1247.	1.0	76
4	Stimulation of Transforming Growth Factor- β 1-Induced Endothelial-To-Mesenchymal Transition and Tissue Fibrosis by Endothelin-1 (ET-1): A Novel Profibrotic Effect of ET-1. <i>PLoS ONE</i> , 2016, 11, e0161988.	1.1	76
5	Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy. <i>Autoimmunity Reviews</i> , 2019, 18, 102396.	2.5	50
6	Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G1052-G1060.	1.6	49
7	Effects of Scleroderma Antibodies and Pooled Human Immunoglobulin on Anal Sphincter and Colonic Smooth Muscle Function. <i>Gastroenterology</i> , 2012, 143, 1308-1318.	0.6	38
8	Systemic Sclerosis Mortality in the United States. <i>Journal of Clinical Rheumatology</i> , 2007, 13, 187-192.	0.5	35
9	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101707.	1.4	22
10	Treatment of rapidly progressive systemic sclerosis: current and futures perspectives. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 31-47.	0.5	20
11	Endothelial cell-specific activation of transforming growth factor- β signaling in mice induces cutaneous, visceral, and microvascular fibrosis. <i>Laboratory Investigation</i> , 2017, 97, 806-818.	1.7	20
12	Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. <i>Arthritis Research and Therapy</i> , 2020, 22, 257.	1.6	20
13	Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition. <i>Translational Research</i> , 2021, 231, 139-158.	2.2	20
14	Abrogation of transforming growth factor- β 2-induced tissue fibrosis in mice with a global genetic deletion of Nox4. <i>Laboratory Investigation</i> , 2019, 99, 470-482.	1.7	19
15	Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 135-139.	1.6	12
16	Primary osteoporosis in men: an unmet medical need. <i>Fertility and Sterility</i> , 2019, 112, 791-798.	0.5	9
17	Systemic sclerosis disease modification clinical trials design: Quo vadis?. <i>Arthritis Care and Research</i> , 2012, 64, n/a-n/a.	1.5	7
18	Severe Eosinophilic Syndrome Associated with the Use of Probiotic Supplements: A New Entity?. <i>Case Reports in Rheumatology</i> , 2012, 2012, 1-3.	0.2	5

#	ARTICLE	IF	CITATIONS
19	Increased expression of interferon regulated and antiviral response genes in CD31+/CD102+ lung microvascular endothelial cells from systemic sclerosis patients with end-stage interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1298-1306.	0.4	5
20	Serine-Threonine Kinase inhibition as antifibrotic therapy: TGF- β 2 and ROCK inhibitors. <i>Rheumatology</i> , 2021, , .	0.9	1
21	Progressive multifocal fibrosing neuropathy: description of a novel disease. <i>Acta Neuropathologica Communications</i> , 2022, 10, 34.	2.4	0
22	Nephrogenic systemic fibrosisâ€“related pulmonary restriction: An under-appreciated manifestation potentially reversible with imatinib therapy. <i>Journal of Scleroderma and Related Disorders</i> , 0, , 239719832210882.	1.0	0